Plasma Lipid Profiling of Three Types of Drug-Induced Liver Injury in Japanese Patients: A Preliminary Study
2020
Kosuke Saito | Tatehiro Kagawa | Keiji Tsuji | Yuji Kumagai | Ken Sato | Shotaro Sakisaka | Naoya Sakamoto | Mitsuhiko Aiso | Shunji Hirose | Nami Mori | Rieko Tanaka | Toshio Uraoka | Kazuhide Takata | Koji Ogawa | Kazuhiko Mori | Motonobu Sato | Takayoshi Nishiya | Kazuhiko Takamatsu | Noriaki Arakawa | Takashi Izumi | Yasuo Ohno | Yoshiro Saito | Hajime Takikawa
Drug-induced liver injury (DILI) is a major adverse event caused by drug treatment, which can be categorized into three types: hepatocellular, mixed, and cholestatic. Although nearly every class of drugs can cause DILI, an overall understanding of lipid profiles in DILI patients is lacking. We used lipidomics to analyze the plasma lipid profiles of patients to understand their hepatic pathophysiology and identify DILI biomarkers. We identified 463 lipids and compared their levels between the acute and recovery phases of the three types of DILI patients. Mixed and cholestatic types demonstrated specific plasma lipid alterations between the phases, but the hepatocellular type did not. Moreover, as specific indicators of mixed-type DILI, levels of several ceramides increased in the acute phase, while those of arachidonic acid-containing ether-linked phosphoglycerolipids decreased. In contrast, as specific indicators of cholestatic-type DILI, levels of palmitic acid-containing saturated or monounsaturated phosphatidylcholines increased in the acute phase, while those of arachidonic acid- or docosahexaenoic acid-containing ether-linked phosphoglycerolipids and phosphatidylinositols decreased. We also identified lipids with a relatively high capacity to discriminate the acute phase from the recovery phase and healthy subjects. These findings may help with understanding the pathophysiology of different DILI types and identify candidate biomarkers.
显示更多 [+] 显示较少 [-]